SS
Therapeutic Areas
Inmunova Pipeline
| Drug | Indication | Phase |
|---|---|---|
| INM004 | Hemolytic uremic syndrome (Shiga toxin‑producing E. coli) | Phase 3 |
Leadership Team at Inmunova
MC
Mariela Cahanovich
Head of Quality
MC
Mariana Colonna
Head of Clinical Research and Regulatory Affairs
CL
Candelaria Lamas
Head of Administration and Finance
VZ
Vanesa Zylberman
Head of R&D and Technical Director
LS
Linus Spatz
Founding Partner and Chief Executive Officer
FG
Fernando Goldbaum
Founding Partner and Scientific Advisor